KORU Medical Systems FY Conference Summary Company Overview - **Company**: KORU Medical Systems (NasdaqCM: KRMD) - **Industry**: Medical Technology (Med Tech) Key Points and Arguments 1. Growth Performance - KORU Medical achieved over 20% growth year-to-date in 2025, driven primarily by international expansion and a strong U.S. market performance [2][3][4] - The international business more than doubled, with significant contributions from prefill expansion technology [2][4] 2. U.S. Market Dynamics - The U.S. business is growing at approximately 10-15%, supported by an 8-10% growth in the primary immune deficiency patient population [3][8] - The company anticipates adding four new drugs to its label, which will further increase patient usage of its systems in early to mid-2026 [3][4] 3. New Product Launches - KORU plans to file for a new pump in the first half of 2026, which is expected to enhance market share and average selling price (ASP) opportunities [6][24] - A pilot study in oncology clinics showed a 97% preference for KORU's platform among nurses, with a market launch anticipated in the second half of 2026 [4][24] 4. Market Growth Projections - The overall U.S. market for immunoglobulin therapy is projected to grow at 8-10%, with only 20% of the population currently on subcutaneous therapy, indicating significant growth potential [8][9] - The company expects to see a doubling of the patient opportunity if secondary immunodeficiency treatments receive reimbursement in the U.S. [9][11] 5. Competitive Landscape - KORU's primary competitor in the U.S. is a privately held company called EMED, which offers mechanical pumps at lower prices [16][19] - In Europe, KORU is gaining market share due to the incompatibility of existing electronic pumps with prefill technology [17][19] 6. Revenue Growth Strategy - KORU anticipates generating an additional $8 million in revenue through U.S. and international growth, as well as new drug launches [20][21] - The company expects international segment growth to exceed 30% [21] 7. Gross Margin Outlook - Current gross margins are projected between 61-63%, with expectations to improve to over 65% in the long term through new product launches and international expansion [31][46] - The company is focused on capital allocation towards gross margin improvement while maintaining top-line growth [46][49] 8. Cash Flow and Capital Allocation - KORU achieved positive cash flow and EBITDA, marking a significant milestone [49] - The company is exploring PFT collaborations to increase market share and revenue potential [50] 9. Regulatory and Market Entry Considerations - KORU does not anticipate significant disruptions from government shutdowns affecting FDA discussions or timelines for new product approvals [53][58] - The company is proactively managing the transition to new products to avoid market pauses or destocking issues [60] Additional Important Insights - The company is seeing a fivefold increase in the number of drugs in development for subcutaneous therapy compared to five years ago, indicating a growing market [18] - KORU's pricing strategy is expected to reflect a lift due to new product launches, with the new pump priced competitively against electronic pumps [41][42]

Core Insights - The article discusses the recent developments in the Hong Kong pharmaceutical sector, particularly focusing on the innovative drug industry, which is experiencing a shift from traditional financing to becoming a showcase for new economy enterprises [3][4][5] - The article emphasizes the importance of external factors such as U.S. Federal Reserve monetary policy, international trade environment, and competition dynamics in influencing the performance of the Hong Kong pharmaceutical sector [6][7][8] Industry Overview - The Hong Kong stock market is transitioning to showcase high-quality companies in sectors like technology, innovative drugs, and new consumption, attracting global capital [3] - Recent adjustments in the Hong Kong pharmaceutical sector are attributed to short-term market sentiment fluctuations and profit-taking, rather than fundamental changes in the industry [4][5] Market Dynamics - The Hang Seng Healthcare Index and the Hong Kong Stock Connect Innovative Drug Select Index are highlighted for their differing coverage and focus, with the former being broader and the latter concentrating on high R&D investment and liquidity companies [2][20] - The innovative drug sector is seeing a significant increase in attention from investors, driven by strong performance in CXO and life sciences services, with profits in these areas growing over 50% year-on-year [19] Policy Environment - Domestic policies are shifting towards supporting genuine innovation, with measures like the establishment of a new drug pricing mechanism and the integration of commercial insurance with the medical insurance directory [7][8] - The article notes that the regulatory environment is improving, which is expected to stabilize profit expectations for pharmaceutical companies [7][8] Investment Strategies - The article advocates for ETF investments in the innovative drug sector due to their diversification, low entry barriers, cost advantages, and high liquidity [21][22] - Suggested investment strategies include dollar-cost averaging and phased investments to manage volatility in the high-risk pharmaceutical sector [24][25] Future Outlook - The long-term growth of the innovative drug sector is supported by a combination of favorable policies, improving industry fundamentals, and the ongoing internationalization of Chinese pharmaceutical companies [15][16] - The article concludes that the current market adjustments provide an opportunity for investors to reassess the long-term value of companies in the innovative drug sector [15][16]

Core Viewpoint - 合富中国 has been awarded a contract for the rental procurement of a magnetic resonance imaging (MRI) immediate navigation radiation therapy system by a leading public hospital in Taiwan, which is recognized as one of the "2025 World's Best Smart Hospitals" [1] Group 1: Project Details - The project involves the procurement of a ViewRay device, which will be sold by 合玺香港台湾分公司 to 合富医疗台湾分公司 for project fulfillment [1] - The payment for the device will be structured as an initial payment plus revenue sharing from the device's operational income [1] Group 2: Business Development - This contract is aimed at advancing the company's business development and increasing revenue opportunities [1] - The successful bid for this project marks a significant milestone for 合富医疗 in expanding its presence in the Taiwanese healthcare market [1]

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments [2] Group 1: Company Overview - The company was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscopic instruments and optical products [7] - The revenue composition of the company is as follows: medical endoscopic instruments 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7] - As of September 30, the company had 5,188 shareholders, a decrease of 1.84% from the previous period, with an average of 23,106 circulating shares per shareholder, an increase of 1.87% [7] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also showing a year-on-year increase of 40.03% [7] - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8] Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3] - The company benefits from a high overseas revenue proportion of 69.12%, aided by the depreciation of the Chinese yuan [3] Group 4: Technical Analysis - The average trading cost of the company's shares is 46.62 yuan, with recent chip reduction slowing down. The current stock price is near a resistance level of 45.45 yuan, indicating potential for a price correction if this level is not surpassed [6]

来源：新浪证券-红岸工作室 融资方面，港通医疗当日融资买入183.27万元。当前融资余额3002.12万元，占流通市值的1.94%，融资 余额低于近一年10%分位水平，处于低位。 融券方面，港通医疗12月1日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量100.00股，融券余额2218.00元，超过近一年90%分位水平，处于高位。 资料显示，四川港通医疗设备集团股份有限公司位于四川省成都市简阳市凯力威工业大道南段356号， 成立日期1998年1月13日，上市日期2023年7月25日，公司主营业务涉及为医疗机构提供以医用气体系统 及医院洁净手术部为核心的医疗专业工程整体方案。主营业务收入构成为：医用洁净装备及系统 55.69%，医用气体装备及系统37.30%，医疗设备及其他产品销售4.06%，运维服务2.81%，其他(补 充)0.14%。 截至11月20日，港通医疗股东户数7895.00，较上期减少2.64%；人均流通股7984股，较上期增加 2.71%。2025年1月-9月，港通医疗实现营业收入3.44亿元，同比减少30.06%；归母净利润-1020.84万 元，同比 ...

Core Viewpoint - The Central Financial Work Conference prioritizes technology finance, emphasizing the role of financial services in empowering technological innovation, with Hangyin Wealth Management being a pioneer in supporting tech innovation through innovative financial products and services [1][2]. Group 1: Company Initiatives - Hangyin Wealth Management has been involved in technology equity investment since 2015, creating the "Jinzuan Venture Capital" series of products, and has provided direct equity financing to over 1,400 tech startups, accumulating an investment scale exceeding 37 billion yuan by June 2025 [1][2]. - The company has established a three-dimensional service system focusing on product innovation, full-process management, and professional capability to effectively connect financial resources with tech enterprises [2][3]. Group 2: Investment Strategies - The company launched the "Jinzuan Venture Capital" private wealth management products to efficiently channel idle social funds into supporting unlisted tech companies, addressing critical gaps in the financing chain for tech enterprises [2][3]. - Hangyin Wealth Management has developed a comprehensive "fundraising-investment-management-exit" process management mechanism, leveraging a decade of experience in tech equity investment [2][3]. Group 3: Sector-Specific Achievements - In the healthcare sector, the company invested 160 million yuan in BJPC Medical Equipment Co., which has developed a brain pacemaker that breaks foreign monopolies in the domestic market [3]. - In the aerospace sector, the company has supported leading enterprises like BJTB Technology Co. and Beijing HTYX Technology Co. through collaborative investments [3]. Group 4: Competitive Advantages - Hangyin Wealth Management benefits from its location in the economically vibrant Yangtze River Delta, where local governments prioritize the development of tech enterprises [4]. - The company leverages the mature ecosystem of its parent bank, Hangzhou Bank, which has over ten years of experience in technology finance, providing unique advantages in industry knowledge and client resources [4]. Group 5: Challenges and Recommendations - Despite its advantages, the company faces challenges in product issuance, performance reference, fund matching, and investment capabilities due to the relatively short history of the industry [5]. - Recommendations for enhancing the capability of wealth management firms in supporting tech innovation include strengthening research capabilities, adapting to the long investment cycles of tech enterprises, and fostering a collaborative industry environment [5][6][7][8].

Market Performance - The Hang Seng Index closed at 26,033, up 0.67% for the day and up 29.78% year-to-date [1] - The Hang Seng Tech Index rose by 0.82% to 5,644, with a year-to-date increase of 26.33% [1] - The Shanghai Composite Index increased by 0.65% to 3,914, with a year-to-date rise of 16.77% [1] - The Dow Jones Index fell by 0.90% to 47,289, with a year-to-date increase of 11.15% [1] Currency and Commodity Overview - The Renminbi Index stands at 97.920, with a 1-month increase of 0.38% and a 6-month increase of 1.79% [2] - Brent crude oil is priced at $63.570 per barrel, down 0.98% over the past month but up 3.13% over the past six months [2] - Gold is priced at $4,256.22 per ounce, with a 1-month increase of 6.37% and a 6-month increase of 25.87% [2] Company News - Kangji Medical's privatization plan has been approved by the Grand Court, with the plan expected to take effect on December 5, 2025 [19] - HashKey Holdings has passed the listing hearing with plans to raise $500 million and seek a listing this month [16] - The real estate crisis in China continues, with major data providers instructed to halt the release of sales data for property companies [17] Economic Indicators - China's official manufacturing PMI for November recorded at 49.2, below market expectations of 49.3 [13] - The non-manufacturing PMI for November was reported at 49.5, also below expectations of 50 [10] - Hong Kong's retail sales value for October increased by 6.9% year-on-year, with online sales rising over 27% [15]

中央金融工作会议将科技金融置于"五篇大文章"首位，明确了金融赋能科技创新的导向。在金融科 技蓬勃发展、科技创新引领未来的时代浪潮中，银行理财正以创新为笔、专业为墨，书写着支持科技创 新的精彩篇章。 一是以创新产品打通资金传导通道。2021年7月，我们设立科创投资部专注耕耘科创股权投资领 域，创新推出"金钻创投"系列私募理财产品，通过封闭式运作募集资金，投向私募股权基金来精准对接 和支持未上市科技企业，打通了理财资金与科创企业之间的"任督二脉"，将社会闲散资金高效汇聚，进 而转化为支持科技创新的长期稳定资本，有效填补了科创企业融资链条中的关键缺口。 二是构建"募投管退"的全流程管理机制。10年以来，杭银理财积累了长期的科创股权投资专业经验 和坚实的客户基础，形成了一套完善的"募投管退"全流程管理机制。 三是构建专业能力，高效稳健创造价值。在组织架构上，特设科创投资部，汇聚精通股权投资、行 业研究、风险管理等多领域的专业人才，形成高效协同的作战团队。同时组建10余人行业研究团队，聚 焦生物医药、商业航天、高端装备、信息技术等重点科创领域开展深度研究。 《金融时报》记者：在这套服务体系支撑下，杭银理财在支持科技创新 ...

Core Insights - A total of 15 stocks on the Sci-Tech Innovation Board experienced block trading on December 1, with a cumulative transaction amount of 360 million yuan [1][2]. Group 1: Trading Overview - There were 41 block trades executed, with a total trading volume of 10.18 million shares [1]. - The stock with the highest transaction amount was Guobo Electronics, which had 6 block trades totaling 7.306 million yuan [1]. - Other notable stocks in terms of transaction amounts included Haitai New Light and Lianyun Technology, with 4.872 million yuan and 3.81983 million yuan respectively [1]. Group 2: Price and Discount Analysis - All stocks involved in block trading were sold at a discount, with the highest discount rates observed in Sanyou Medical, Delong Laser, and Puyuan Information, at 16.46%, 12.68%, and 11.99% respectively [1][2]. - The average decline for stocks that underwent block trading was 0.46%, while the Sci-Tech 50 Index rose by 0.72% [1]. Group 3: Institutional Participation - Institutional transactions accounted for 18 trades involving 5 stocks, with Guobo Electronics leading in institutional buy amounts at 68.9976 million yuan [2]. - The stocks with the highest net inflow of funds included Hush Silicon Industry, Aerospace Software, and Haitai New Light, with net inflows of 20.4385 million yuan, 18.4593 million yuan, and 2.7452 million yuan respectively [2]. Group 4: Detailed Trading Data - A detailed table of block trading data includes various stocks, their transaction counts, volumes, average transaction prices, discount rates relative to closing prices, and total transaction amounts [3].

新华社柏林12月1日电 题：德企的选择，是中欧合作共赢生动写照 新华社记者李函林 大众集团近日在合肥启用全流程研发测试中心，首次实现在德国总部以外的新车平台"从概念到上 市"全链条开发，使整车研发周期缩短约三成，助力其更快响应全球最具活力汽车市场的需求。将核心 研发链条落地中国，不仅为顺应市场，更体现出对中国技术优势和产业生态的高度认可。 最新统计数据进一步印证了中德合作的韧性与潜力。2025年前9个月，中德双边贸易总额达1859亿 欧元，同比增长0.6％，中国再次成为德国最大贸易伙伴。双方贸易规模的稳步增长，凸显中德经贸互 补性：德国以工程技术和工业基础闻名，而中国企业以研发速度和技术进步著称，优势互补为企业开辟 了广阔发展空间。 在全球产业格局深刻调整、地缘竞争不断加剧的当下，德国企业持续加码中国市场，以务实行动为 中欧合作写下坚实注脚。尽管政治杂音和"去风险"叙事时有起伏，但德企以投资和研发布局中国的脚步 表明：以经济效益与技术创新为核心的理性判断，仍主导着企业的全球决策，而优势互补与互利共赢依 旧是中欧合作的稳固底色。 与此同时，中国企业也在德国稳步推进投资。德国联邦外贸与投资署数据显示，2024年， ...